tiprankstipranks
Soligenix Inc (SNGX)
:SNGX

Soligenix (SNGX) AI Stock Analysis

Compare
651 Followers

Top Page

SN

Soligenix

(NASDAQ:SNGX)

37Underperform
Soligenix's overall score is heavily impacted by its weak financial performance, characterized by ongoing losses and high leverage. Technical indicators further suggest a bearish outlook with downward momentum. The negative P/E ratio and lack of dividends contribute to an unattractive valuation, making the stock a high-risk investment.

Soligenix (SNGX) vs. S&P 500 (SPY)

Soligenix Business Overview & Revenue Model

Company DescriptionSoligenix, Inc. (SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates in two segments: BioTherapeutics and Public Health Solutions. The BioTherapeutics segment is dedicated to developing products for orphan diseases and areas of unmet medical need, including proprietary formulations of oral mucositis, cutaneous T-cell lymphoma, and pediatric Crohn's disease. The Public Health Solutions segment aims to develop vaccines and therapeutics for military and civilian applications in areas such as ricin toxin, melioidosis, Ebola virus, and radiation exposure.
How the Company Makes MoneySoligenix generates revenue primarily through strategic partnerships, government contracts, and grants. In its BioTherapeutics segment, the company seeks to commercialize its proprietary drug candidates by partnering with larger pharmaceutical companies that have the resources to support late-stage clinical trials and distribution. These partnerships often involve upfront payments, milestone payments, and royalties on product sales. In the Public Health Solutions segment, Soligenix benefits from government funding and contracts, particularly from agencies focused on biodefense and public health initiatives. This funding supports the development of vaccines and therapeutics, providing a significant revenue stream while advancing their product pipeline.

Soligenix Financial Statement Overview

Summary
Soligenix faces significant financial challenges across its income statement, balance sheet, and cash flow statement. Consistent losses, high leverage, and negative cash flow trends are evident. There are some signs of improvement in equity and liquidity, but overall, the financial health remains weak.
Income Statement
30
Negative
Soligenix's income statement reflects significant challenges, with consistently negative EBIT and net income indicating ongoing operating losses. Revenue growth is volatile, with a recent decline in TTM revenue compared to previous annual figures. Margins remain under pressure, as evidenced by negative gross and net profit margins, suggesting profitability challenges.
Balance Sheet
40
Negative
The balance sheet reveals a strained financial position, with a high debt-to-equity ratio and negative equity in past periods, though equity has improved recently. The company's equity ratio has improved, but overall leverage remains high, posing financial risk. Cash reserves are solid relative to liabilities, providing some liquidity cushion.
Cash Flow
35
Negative
Cash flow analysis shows negative free cash flow and operating cash flow, indicating challenges in generating cash from operations. Recent improvements in financing activities have bolstered cash reserves, but the reliance on external financing is a concern. The operating cash flow to net income ratio highlights ongoing cash generation issues.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
364.18K839.36K948.91K824.27K2.36M4.63M
Gross Profit
20.09K97.31K398.09K95.63K538.50K1.06M
EBIT
-8.23M-7.70M-14.11M-12.97M-18.49M-10.11M
EBITDA
-7.84M-7.85M-14.11M-12.23M-18.23M-9.36M
Net Income Common Stockholders
-7.10M-6.14M-13.80M-12.55M-17.69M-9.36M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.98M8.45M13.36M26.04M18.68M5.42M
Total Assets
10.49M9.80M14.28M26.87M19.89M7.78M
Total Debt
0.003.49M10.24M9.96M10.51M127.22K
Net Debt
-8.98M-4.95M-3.12M-16.08M-8.17M-5.29M
Total Liabilities
4.21M7.27M16.75M16.15M16.15M6.32M
Stockholders Equity
6.28M2.52M-2.47M10.72M3.74M1.46M
Cash FlowFree Cash Flow
-8.00M-8.60M-12.66M-11.75M-11.46M-7.54M
Operating Cash Flow
-8.00M-8.60M-12.65M-11.74M-11.45M-7.51M
Investing Cash Flow
-1.20M0.00-13.07K-11.79K-7.15K-24.71K
Financing Cash Flow
7.47M3.66M76.82K19.06M24.68M4.01M

Soligenix Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.32
Price Trends
50DMA
2.49
Negative
100DMA
2.96
Negative
200DMA
3.56
Negative
Market Momentum
MACD
-0.05
Negative
RSI
45.88
Neutral
STOCH
64.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Negative. The current price of 2.32 is below the 20-day moving average (MA) of 2.33, below the 50-day MA of 2.49, and below the 200-day MA of 3.56, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.88 is Neutral, neither overbought nor oversold. The STOCH value of 64.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNGX.

Soligenix Risk Analysis

Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Soligenix Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$54.83M-118.50%1.80%33.06%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
37
Underperform
$5.82M-139.80%-100.00%76.13%
32
Underperform
$9.35M234.90%46.67%
CVCVM
32
Underperform
$25.12M-227.76%30.96%
20
Underperform
$1.28M197.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNGX
Soligenix
2.30
-7.89
-77.43%
CVM
Cel-Sci
0.30
-1.81
-85.78%
ADXS
Advaxis
0.03
-0.64
-95.52%
BCLI
Brainstorm Cell Therapeutics
1.56
-3.37
-68.36%
CTSO
Cytosorbents
1.07
0.10
10.31%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.